JPWO2019195712A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019195712A5 JPWO2019195712A5 JP2020554521A JP2020554521A JPWO2019195712A5 JP WO2019195712 A5 JPWO2019195712 A5 JP WO2019195712A5 JP 2020554521 A JP2020554521 A JP 2020554521A JP 2020554521 A JP2020554521 A JP 2020554521A JP WO2019195712 A5 JPWO2019195712 A5 JP WO2019195712A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- compound
- administration
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 27
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims 21
- 239000002202 Polyethylene glycol Substances 0.000 claims 14
- 229920001223 polyethylene glycol Polymers 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 150000001413 amino acids Chemical group 0.000 claims 9
- 239000012472 biological sample Substances 0.000 claims 6
- 108010078015 Complement C3b Proteins 0.000 claims 5
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 108010027437 compstatin Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000008595 infiltration Effects 0.000 claims 2
- 238000001764 infiltration Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010055690 Foetal death Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044541 Traumatic shock Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003460 anti-nuclear Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000037896 autoimmune cutaneous disease Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000002025 microglial effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 230000004263 retinal angiogenesis Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000008359 toxicosis Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862654055P | 2018-04-06 | 2018-04-06 | |
| US62/654,055 | 2018-04-06 | ||
| PCT/US2019/026040 WO2019195712A2 (fr) | 2018-04-06 | 2019-04-05 | Analogues de la compstatine possédant une solubilité augmentée et des propriétés pharmacocinétiques améliorées |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521108A JP2021521108A (ja) | 2021-08-26 |
| JP2021521108A5 JP2021521108A5 (fr) | 2021-10-07 |
| JPWO2019195712A5 true JPWO2019195712A5 (fr) | 2022-04-01 |
| JP7423070B2 JP7423070B2 (ja) | 2024-01-29 |
Family
ID=66669013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554521A Active JP7423070B2 (ja) | 2018-04-06 | 2019-04-05 | 増加した溶解度および改善された薬物動態特性を有するコンプスタチンアナログ |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11884747B2 (fr) |
| EP (2) | EP3645550B1 (fr) |
| JP (1) | JP7423070B2 (fr) |
| CN (1) | CN112334477A (fr) |
| AU (1) | AU2019247467B2 (fr) |
| BR (1) | BR112020020369A2 (fr) |
| CA (1) | CA3096078A1 (fr) |
| DK (1) | DK3645550T3 (fr) |
| ES (1) | ES2904471T3 (fr) |
| HU (1) | HUE057693T2 (fr) |
| IL (1) | IL277690A (fr) |
| MX (1) | MX2020010520A (fr) |
| PL (1) | PL3645550T3 (fr) |
| PT (1) | PT3645550T (fr) |
| RU (1) | RU2020136249A (fr) |
| WO (1) | WO2019195712A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019247467B2 (en) * | 2018-04-06 | 2023-01-19 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with increased solubility and improved pharmacokinetic properties |
| CN111265651A (zh) * | 2020-02-29 | 2020-06-12 | 华中科技大学同济医学院附属同济医院 | 补体c3抑制剂cp40-kk在制备防治肺动脉高压病药物中的应用 |
| WO2023183705A1 (fr) * | 2022-03-23 | 2023-09-28 | Robert Coifman | Utilisation de chaînes d'acides aminés non informationnelles pour modifier les propriétés de solubilité de peptides |
| WO2024110878A1 (fr) | 2022-11-24 | 2024-05-30 | Amyndas Pharmaceuticals Us Llc | Analogues de compstatine pour thérapie à base de vecteurs |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US761A (en) | 1838-05-30 | Improved circulating sugar-boiler | ||
| US6129A (en) | 1849-02-20 | Washbtjrn race | ||
| FR2295746A1 (fr) | 1974-12-23 | 1976-07-23 | Francaise Coop Pharma | Nouveaux derives du tryptophane a activite nerveuse centrale renforcee |
| IT1179866B (it) | 1984-12-12 | 1987-09-16 | Rotta Research Lab | Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono |
| US4576750A (en) | 1985-04-22 | 1986-03-18 | Merck & Co., Inc. | Tryptophan derivative |
| US4969912A (en) | 1988-02-18 | 1990-11-13 | Kelman Charles D | Human collagen processing and autoimplant use |
| US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| US5167960A (en) | 1988-08-03 | 1992-12-01 | New England Deaconess Hospital Corporation | Hirudin-coated biocompatible substance |
| US5201764A (en) | 1990-02-28 | 1993-04-13 | Autogenesis Technologies, Inc. | Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom |
| BR9306038A (pt) | 1992-02-28 | 1998-01-13 | Univ Texas | Hidrogéis biodegradáveis fotopolimerizáveis como materiais de contato de tecidos e condutores de liberação controlada |
| US5492135A (en) | 1992-09-09 | 1996-02-20 | Devore; Dale P. | Collagen modulators for use in photoablation excimer laser keratectomy |
| US5955343A (en) | 1992-12-28 | 1999-09-21 | Massachusetts Institute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| US5322802A (en) | 1993-01-25 | 1994-06-21 | North Carolina State University At Raleigh | Method of fabricating silicon carbide field effect transistor |
| US5667839A (en) | 1993-01-28 | 1997-09-16 | Collagen Corporation | Human recombinant collagen in the milk of transgenic animals |
| WO1995003009A1 (fr) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Methode de traitement de la degenerescence maculaire |
| WO1995003807A1 (fr) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Traitement de la degenerescence maculaire due au vieillissement |
| US5593854A (en) | 1994-02-16 | 1997-01-14 | Becton Dickinson And Company | Data analysis method for use with fluorescent bacterial sensors |
| US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
| JP2000505068A (ja) | 1996-03-13 | 2000-04-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 補体活性化を阻害する新規ペプチド類 |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US5775970A (en) | 1996-06-27 | 1998-07-07 | Klees; Daniel J. | Toy animal adjustable leash with sound and light |
| US6221621B1 (en) | 1997-03-06 | 2001-04-24 | Bard Diagnostic Sciences, Inc. | Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated |
| US6169057B1 (en) | 1997-09-04 | 2001-01-02 | The Regents Of The University Of California | Use of tryptophan and analogs as plant growth regulators |
| WO1999013899A1 (fr) | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides et peptidomimetiques inhibant l'activation du complement |
| US6214790B1 (en) | 1998-04-10 | 2001-04-10 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| EP1154734B1 (fr) | 1999-02-12 | 2014-10-01 | ProChon Biotech Ltd. | Systeme injectable a base de collagene pour l'administration de cellules |
| US6692759B1 (en) | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
| EP2311480B1 (fr) | 2002-09-20 | 2013-06-26 | The Trustees of The University of Pennsylvania | Analogues de la compstatine dotés d'une activité améliorée |
| JP2007513192A (ja) | 2004-10-04 | 2007-05-24 | ノベタイド，リミティド | ペプチド用の対イオン交換法 |
| DK1951279T3 (en) | 2005-10-08 | 2017-07-31 | Apellis Pharmaceuticals Inc | COMPSTATIN AND ANALOGUES THEREOF FOR EYE DISEASES |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| RU2474586C2 (ru) | 2005-11-28 | 2013-02-10 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Эффективные аналоги компстатина |
| BRPI0717505B8 (pt) | 2006-10-04 | 2021-05-25 | Novo Nordisk As | conjugado de peptídeo e formulação farmacêutica |
| WO2008153963A1 (fr) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennsylvania | Structure d'un complexe compstatin-c3 et son utilisation pour l'élaboration rationnelle de substances thérapeutiques |
| CA2760839C (fr) | 2009-05-01 | 2019-02-12 | The Trustees Of The University Of Pennsylvania | Compstatine modifiee avec squelette peptidique et modifications c-terminales |
| US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| WO2012040259A2 (fr) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Compstatine modifiée ayant des propriétés de stabilité et de liaison améliorées |
| EP2707384B1 (fr) | 2011-05-11 | 2022-04-06 | Apellis Pharmaceuticals, Inc. | Analogues de la compstatine ciblés, à longue durée d'action, réactifs aux cellules, et leurs utilisations |
| WO2012178083A1 (fr) | 2011-06-22 | 2012-12-27 | Apellis Pharmaceuticals, Inc. | Méthodes de traitement de troubles chroniques au moyen d'inhibiteurs de complément |
| ES2766755T3 (es) | 2011-09-07 | 2020-06-15 | Univ Pennsylvania | Análogos de compstatina con propiedades farmacocinéticas mejoradas |
| CA2855770A1 (fr) | 2011-11-17 | 2013-05-23 | Cebix Ab | Peptide c pegyle |
| WO2013142362A1 (fr) | 2012-03-19 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Régulateur d'activation du complément et ses utilisations |
| US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| WO2014028861A1 (fr) | 2012-08-17 | 2014-02-20 | Apellis Pharmaceuticals, Inc. | Détection de drusen à risque élevé |
| ES2780674T3 (es) | 2012-11-15 | 2020-08-26 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
| WO2014078734A2 (fr) * | 2012-11-15 | 2014-05-22 | Apellis Pharmaceuticals, Inc. | Analogues de la compstatine réactifs aux cellules, à longue durée d'action ou ciblés et compositions et méthodes associées |
| WO2014152391A1 (fr) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Analogues de compstatine pénétrant dans les cellules et leurs utilisations |
| WO2014152931A1 (fr) | 2013-03-15 | 2014-09-25 | Enginuity Worldwide, LLC | Pastille de combustible de biomasse résistant à l'humidité et procédé de fabrication |
| IL258525B2 (en) | 2015-10-07 | 2023-03-01 | Apellis Pharmaceuticals Inc | Dosing regimens |
| PE20201254A1 (es) | 2018-02-27 | 2020-11-16 | Zp Spv 3 K/S | Analogos de compstatina y sus usos medicos |
| AU2019247467B2 (en) * | 2018-04-06 | 2023-01-19 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with increased solubility and improved pharmacokinetic properties |
-
2019
- 2019-04-05 AU AU2019247467A patent/AU2019247467B2/en active Active
- 2019-04-05 RU RU2020136249A patent/RU2020136249A/ru unknown
- 2019-04-05 BR BR112020020369-6A patent/BR112020020369A2/pt unknown
- 2019-04-05 US US17/045,018 patent/US11884747B2/en active Active
- 2019-04-05 PL PL19727126T patent/PL3645550T3/pl unknown
- 2019-04-05 ES ES19727126T patent/ES2904471T3/es active Active
- 2019-04-05 JP JP2020554521A patent/JP7423070B2/ja active Active
- 2019-04-05 MX MX2020010520A patent/MX2020010520A/es unknown
- 2019-04-05 HU HUE19727126A patent/HUE057693T2/hu unknown
- 2019-04-05 EP EP19727126.5A patent/EP3645550B1/fr active Active
- 2019-04-05 WO PCT/US2019/026040 patent/WO2019195712A2/fr unknown
- 2019-04-05 EP EP21205763.2A patent/EP4011905A3/fr active Pending
- 2019-04-05 CA CA3096078A patent/CA3096078A1/fr active Pending
- 2019-04-05 CN CN201980030725.6A patent/CN112334477A/zh active Pending
- 2019-04-05 DK DK19727126.5T patent/DK3645550T3/da active
- 2019-04-05 PT PT197271265T patent/PT3645550T/pt unknown
-
2020
- 2020-01-28 US US16/774,934 patent/US10800812B2/en active Active
- 2020-09-30 IL IL277690A patent/IL277690A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69934425T2 (de) | Thrombopoietin substitute | |
| JP2021521108A5 (fr) | ||
| KR100298763B1 (ko) | 말초신경병의예방및치료 | |
| AU2016225913B2 (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| RU2020136249A (ru) | Аналоги компстатина с увеличенной растворимостью и улучшенными фармакокинетическими свойствами | |
| KR20190036520A (ko) | 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물 | |
| US10905773B2 (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| JPH04218000A (ja) | 修飾ポリペプチド | |
| JP2009513689A5 (fr) | ||
| US20220211799A1 (en) | Compositions and methods for modulating complement activity | |
| CN109134664B (zh) | 一种经修饰的生长分化因子及其制备方法和应用 | |
| SK9712003A3 (en) | Neublastin variants, fusion proteins containing neublastin variant, method for the preparation thereof, pharmaceutical composition containing same and their use | |
| JPWO2019195712A5 (fr) | ||
| JPH10509460A (ja) | 自己免疫疾患の進行を阻害するための処理方法 | |
| JP2011078434A (ja) | 変異ニューブラスチンのポリマー結合体 | |
| JP2022512541A (ja) | Ｐｄ－１系キメラタンパク質を含む併用療法 | |
| JP2002500161A (ja) | 神経栄養性および鎮痛性のレトロインバースペプチド | |
| US9012605B2 (en) | Crystalline polypeptides | |
| CN110139659B (zh) | 用于治疗干燥综合征的肽 | |
| US7479539B1 (en) | Hedgehog fusion proteins | |
| AU2800101A (en) | DNA sequences and secreted proteins encoded thereby |